About

About Limula Cell and gene therapy (CGT) manufacturing is outdated, fragmented, and unable to scale. Manual, labor-intensive processes developed in academic labs lead to high costs, long tech transfer timelines, and regulatory hurdles, causing 30 to 40 percent of projects to fail even when therapies are clinically effective. In 2023, only 2 percent of the 500,000 patients eligible for approved CAR-T therapies received treatment, underscoring the urgent need for scalable, robust manufacturing solutions. Limula is addressing this challenge. Based in Lausanne, Switzerland, the company is on a mission to make highly personalised CGT products accessible to patients in need, at reasonable cost, wherever they are. Limula offers a smart platform, LimONE, that enables end-to-end automation for on-demand, scalable manufacturing of personalised cell therapies at the point of care. Its unique, proprietary technology consolidates every step of the production process into a single instrument, significantly reducing costs by minimising skilled manual labour, equipment, and infrastructure requirements.